Call Options on HOLX on 12/20/2021

Hologic, Inc. (HOLX) develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally.

It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.

The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products.

In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures.

Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures.

The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

Hologic should have a strong earnings report on January 31, with an expected earnings report of $1.14 and revenue of $1.08 billion.

Last Trade: $77.71

Trading Range: $60.10 - $85.00

Trade Buy 1 January $75.00 Call at $4.50 For a net debit of $4.50 Profit/Loss Analysis Breakeven at $79.50 Maximum profit is unbounded Maximum loss is ($450.00) at strike of $75.00 Closing Summary Sold 1 January $75.00 Call at $0.00

Position closed on 1/21/2022 at price of $0.00 with a -100.00% loss in 32 days.

Back to Portfolio